ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosisXavier Montalbán, Frauke Zipp, Ralf Gold et al.|Multiple Sclerosis Journal|2018Cited by 706
Multiple sclerosis progression: time for a new mechanism-driven frameworkTanja Kuhlmann, Emmaunelle Waubant, Marcello Moccia et al.|The Lancet Neurology|2022Cited by 624
Clinical and imaging assessment of cognitive dysfunction in multiple sclerosisMaria A. Rocca, Massimo Filippi, Maria Pia Amato et al.|The Lancet Neurology|2015Cited by 523
Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical EventDarin T. Okuda, Christine Lebrun‐Frénay, Aksel Sıva et al.|PLoS ONE|2014Cited by 332
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteriaXavier Montalbán, Heinz Wiendl, Christine Lebrun‐Frénay et al.|The Lancet Neurology|2025Cited by 314